NovaBay Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
SDEV$0.85-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
|---|
The financial statements required by this Item 8 are set forth below. Our financial information is set forth in Item 7 of this annual report and is hereby incorporated into this Item 8 by reference.
| INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | |
|---|---|
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 199) | 41 |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 100) | 42 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 44 |
| Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024 | 45 |
| Consolidated Statements of Stockholders’ Deficit for the Years Ended December 31, 2025 and 2024 | 46 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024 | 47 |
| Notes to Consolidated Financial Statements | 49 |
- 40 -
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.